| P/E (FY) | — | Sales (TTM) | $53.5M |
| Earnings (TTM) | -$31.3M | ROE | −132.53% |
| Net Margin | −80.05% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $52.9M | Trading Days | 1188 |
| 52W High | 12.82 |
| 52W Low | 6.50 |
| % Off High | −28.61% |
| YTD | 1.51% | 1Y | −4.74% |
| 3Y | −77.52% | Since incept. (ann.) | −49.02% |
| Ann. Volatility (1Y) | 47.81% | Ann. Volatility (3Y) | 128.24% |
| Sharpe (1Y) | 0.13 | Sharpe (3Y) | 0.14 |
| Max Drawdown (1Y) | −40.89% | Max Drawdown (3Y) | −82.76% |
| Beta (3Y, vs SPY) | −0.84 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
| DWTX | Dogwood Therapeutics, Inc. | $52.1M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M | — |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| CTOR | CITIUS ONCOLOGY, INC. | $50.3M | — |
| ELTX | Elicio Therapeutics, Inc. | $56.3M | — |
| GOSS | Gossamer Bio, Inc. | $48.1M | — |
| ANVS | Annovis Bio, Inc. | $58.6M | — |
| PMVP | PMV Pharmaceuticals, Inc. |
| $58.7M |
| — |
| CING | Cingulate Inc. | $60.1M | — |
